Navigation Links
Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission
Date:7/30/2014

of Regeneron to manufacture and manage supply chains for multiple products and product candidates; coverage and reimbursement determinations by third-party payers, including Medicare and Medicaid; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its sales or other financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi and Bayer HealthCare LLC, to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto.  A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2013 and its Form 10-Q for the quarter ended March 31, 2014.  The reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update publicly any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise. Contacts Sanofi:Media Relations

Investor Relations Jack Cox

Sebastien MartelTel: +33 (0) 1 53 77 94 74

Tel: +33 (0)1 53 77 45 45Mobile: +33 (0) 6 78 52 05 36

E-mail: IR@sanofi.com E-mail: Jack.Cox@sanofi.com <
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Regeneron to Report Second Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2014
2. Regenerons Chief Executive Officer and Chief Scientific Officer named "Management Team of the Year" by Scrip Intelligence
3. Regeneron Named Top Employer in the Global Biopharmaceutical Industry for the Second Year in a Row
4. After 18 Months On the U.S. Market, Regenerons Eylea Captures One-Fifth of First-Line Intravitreal Pharmacotherapy Share Among Wet Age-Related Macular Degeneration (AMD) Patients
5. Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
6. Regeneron Reports First Quarter 2013 Financial and Operating Results
7. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
8. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
9. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
10. Regeneron Announces March 2012 Investor Conference Presentations
11. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 2015 /CNW/ - Bioenterprise Corporation is pleased to announce that ... Charlottetown , PEI.  Bioenterprise has established a ... Council for the commercialization of agricultural technologies and innovations. ... PEI ADAPT.  They have been at the heart of ... explains Dave Smardon , President & CEO of ...
(Date:4/16/2015)... DIEGO , April 16, 2015  AnaptysBio, ... development of therapeutic antibodies, today announced the ... antibody program into IND-enabling studies. The Company,s ... novel treatment for generalized pustular psoriasis (GPP), ... unmet medical need. ANB019 is wholly owned within ...
(Date:4/16/2015)... 2015  EMD Serono today announced the US ... Germany , appointed Alise Reicin , ... Clinical Development.  Dr. Reicin brings extensive research and ... and Immunology. She is an accomplished pharmaceutical executive ... Vice President in various capacities across R&D at ...
(Date:4/16/2015)... 16, 2015 Fairleigh Dickinson University ... Gulfo to become the Executive Director of the ... announced the kick-off of the Initiative for Patient ... Dr. Gulfo, under the Rothman Institute of Innovation ... and in collaboration with FDU’s School of Pharmacy’s ...
Breaking Biology Technology:Bioenterprise Corporation Expands into the Maritimes 2AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3
... DIEGO, Nov. 6 Halozyme Therapeutics, Inc.,(Nasdaq: ... targeting the extracellular matrix for the drug delivery,endocrinology, ... the three and nine months ended September 30, ... been stronger and I am,pleased with the initiation ...
... 6 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President,and CEO of ... a,corporate overview of the Company at the Rodman & ... at 11:10 a.m. ET. The,event will be held at ... A live audio webcast of the presentation will ...
... Highlights:, * Submitted NDA with FDA for NGX-4010 for management of pain ... ... EMEA,s scheduled Day 120 questions regarding MAA under ... SAN MATEO, Calif., Nov. 6 NeurogesX, Inc.,(Nasdaq: NGSX ), a biopharmaceutical ...
Cached Biology Technology:Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 2Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 3Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 4Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 5Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 6Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 7Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 8Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference 2NeurogesX Reports Third Quarter 2008 Results 2NeurogesX Reports Third Quarter 2008 Results 3NeurogesX Reports Third Quarter 2008 Results 4NeurogesX Reports Third Quarter 2008 Results 5NeurogesX Reports Third Quarter 2008 Results 6NeurogesX Reports Third Quarter 2008 Results 7NeurogesX Reports Third Quarter 2008 Results 8NeurogesX Reports Third Quarter 2008 Results 9
(Date:3/20/2015)... Conn. , March 20, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... smart wallet is one of the products featured in ... March 20th at 11:00 PM EST on the DIY ... to Las Vegas , site of ...
(Date:3/18/2015)... March 18, 2015 As mobile payments ... revolutionary smart wallets and apps continue to be introduced into ... in the mobile payment industry in focus today are:  NXT-ID, ... (NYSE: BABA ), Apple Inc. (NASDAQ: ... Facebook Inc. (NASDAQ: FB ) NXT-ID, ...
(Date:3/17/2015)... NEW YORK , March 17, 2015 /PRNewswire/ ... , the largest exhibition for service robots ever ... . RoboUniverse takes place on May 11-13, 2015 ... Sponsors and exhibitors for the event include: Acorn ... Motion Control; EZ-Robot; Infranor; Kinova Robotics; Littler; NewBotic ...
Breaking Biology News(10 mins):NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
... This press release is available in ... have found that unmanned aerial vehicles (UAVs), a tool used ... on changing land-use patterns across vast tracts of western rangeland. ... to survey vast, remote rangelands to see how they are ...
... sorghum hybrid that does not flower and accumulates as much ... may help the bioenergy industry, according to a study appearing ... Sciences. A team at Texas AgriLife Research has ... proceedings. "For energy crops, we want to prevent plants ...
... DigitalPersona, Inc. , a global provider of ... portfolio of fingerprint biometric Civil ID solutions ... Tampa, Fla. Supported by the National Institute of Standards ... the Biometric Consortium Conference is focused on biometric technologies ...
Cached Biology News:A labor saving way to monitor vast rangelands 2Gene controlling flowering boosts energy production from sorghum 2Gene controlling flowering boosts energy production from sorghum 3DigitalPersona Showcases Fingerprint Biometrics for Civil ID Applications at the Biometric Consortium Conference 2DigitalPersona Showcases Fingerprint Biometrics for Civil ID Applications at the Biometric Consortium Conference 3
Required to perform reference file generation, flatfield calibration and performance verification processes on the GSD-501...
Applications: Immunohistochemistry, ISH, FISH, CISH....
Applications: Immunohistochemistry, ISH, FISH, CISH....
Polypropylene test tube racks, used in Thermo Forma's line of Test Tube Rack holders...
Biology Products: